Westlake Village BioPartners managing directors (from L-R) David Allison and Mira Chaurushiya, and founding managing director Beth Seidenberg
Westlake attracts another $450M to fuel startups in LA's nascent biotech scene
“If it’s not broken, let’s not try to fix it.”
That’s the motto behind biotech VC firm Westlake Village BioPartners, which said Monday that most of its existing investors returned for a $450 million third fund. The firm plans to incubate more hometown Los Angeles startups, follow the same CEO-first model that worked for its IPO star Acelyrin and breathe new life into clinical-stage assets developed by biopharmas.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
